Tourlite Capital Management, an investment management firm, released its third quarter 2024 investor letter, a copy of which can be downloaded here. Tourlite Fund, LP Founder Class returned 4.5% for ...

Arbutus continues to consult closely with and support its exclusive licensee, Genevant Sciences, to protect and defend Arbutus’s intellectual property, which is the subject of on-going lawsuits ...

April 11 (Reuters) - A U.S. appeals court handed Moderna Inc (MRNA.O), opens new tab a win on Tuesday, affirming a decision to cancel an Arbutus Biopharma Corp (ABUS.O), opens new tab patent related ...

Roivant Sciences and Moderna Therapeutics, two of the most highly-funded and controversial companies in the biotechnology world, are headed for a collision course over medical technology. On Monday, ...

Arbutus Biopharma is dumping one of its Roivant-backed programs after two healthy people in a phase 1 study developed acute hepatitis—the very disease the drug was supposed to treat. The company was ...

Arbutus Biopharma (NASDAQ:ABUS) quickly soared 19% after a claim construction order in a Covid vaccine patent dispute with Moderna (NASDAQ:MRNA) according to a court filing on Wednesday. Moderna fell ...

It’s a David-and-Goliath fight between two unprofitable startups. Moderna Therapeutics is valued by its private investors at $5 billion, as it promises to create a new kind of medicine that will turn ...